MRNA vaccine study for preventing genital herpes
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You are generally healthy and have no history of genital herpes in the last 6 months.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You have not used certain medications, such as steroids for more than 14 days or anti-herpes drugs, in the past 6 months.
- You have not had a recent vaccination (live vaccine within 14 days or other vaccines within 7 days).
- You do not have a history of severe allergies, autoimmune disease, cancer, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA vaccine to prevent shingles (herpes zoster). It checks if the vaccine is safe and helps your body build immunity. It's for adults aged 40 or older (phase 1) or 50+ (phase 2).
This study tests an investigational medication called UB-621, given as repeated doses, to see if it is safe and effective in reducing recurrent genital herpes outbreaks in adults. If you have frequent outbreaks (6 to 12 per year), this trial might help you find a new treatment option.
This study tests a new vaccine to protect against shingles (herpes zoster), a painful skin infection that can affect people as they age. You would receive the vaccine and be monitored to see if it's safe and how your body responds.
This trial is testing an experimental mRNA vaccine for preventing shingles. It aims to see if the vaccine is safe and triggers a good immune response in people aged 50 to 79.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests a new shingles vaccine for healthy adults 40 and older. It aims to see if the vaccine is safe and helps protect against shingles.
Hear when a new Genital Herpes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.